Literature DB >> 3159472

Suppression of generation of concomitant antitumor immunity by passively transferred suppressor T cells from tumor-bearing donors.

I Bursuker, R J North.   

Abstract

Infusion of normal recipient mice with suppressor T cells from donors bearing a progressive Meth A fibrosarcoma results in a diminished capacity of the recipients to generate concomitant and postexcision antitumor immunity. The passive transfer of suppressor cells which prevented the generation of immunity to the Meth A fibrosarcoma did not affect the capacity of the recipients to reject an allogeneic tumor. The data provides direct evidence in support of the hypothesis that suppressor T cells, generated at later stages of growth of Meth A fibrosarcoma, function to down-regulate an already acquired mechanism of concomitant immunity.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3159472     DOI: 10.1007/bf00199229

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  13 in total

1.  Immunity to methylcholanthrene-induced sarcomas.

Authors:  R T PREHN; J M MAIN
Journal:  J Natl Cancer Inst       Date:  1957-06       Impact factor: 13.506

Review 2.  Xenogeneic monoclonal antibodies to mouse lymphoid differentiation antigens.

Authors:  J A Ledbetter; L A Herzenberg
Journal:  Immunol Rev       Date:  1979       Impact factor: 12.988

Review 3.  Concomitant tumor immunity and the resistance to a second tumor challenge.

Authors:  E Gorelik
Journal:  Adv Cancer Res       Date:  1983       Impact factor: 6.242

4.  Development of protective immunity against bacterial and viral infections in tumor-bearing mice coincident with suppression of tumor immunity.

Authors:  P F Bonventre; A D Nickol; E J Ball; J G Michael; H C Bubel
Journal:  J Reticuloendothel Soc       Date:  1982-07

Review 5.  Suppressor T cells and the immune response to tumors.

Authors:  S Schatten; R D Granstein; J A Drebin; M I Greene
Journal:  Crit Rev Immunol       Date:  1984       Impact factor: 2.214

6.  Gamma-irradiation facilitates the expression of adoptive immunity against established tumors by eliminating suppressor T cells.

Authors:  R J North
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

7.  T cell-mediated immunosuppression as an obstacle to adoptive immunotherapy of the P815 mastocytoma and its metastases.

Authors:  E S Dye; R J North
Journal:  J Exp Med       Date:  1981-10-01       Impact factor: 14.307

8.  Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells.

Authors:  R J North
Journal:  J Exp Med       Date:  1982-04-01       Impact factor: 14.307

9.  Expression of passively transferred immunity against an established tumor depends on generation of cytolytic T cells in recipient. Inhibition by suppressor T cells.

Authors:  C D Mills; R J North
Journal:  J Exp Med       Date:  1983-05-01       Impact factor: 14.307

10.  Generation and decay of the immune response to a progressive fibrosarcoma. I. Ly-1+2- suppressor T cells down-regulate the generation of Ly-1-2+ effector T cells.

Authors:  R J North; I Bursuker
Journal:  J Exp Med       Date:  1984-05-01       Impact factor: 14.307

View more
  7 in total

1.  In vitro expression of secondary antitumor immunity by in vitro tumor-sensitized T cells: inhibition by tumor-induced suppressor T cells.

Authors:  Z Kaymakcalan; G L Spitalny; I Bursuker
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

2.  Reciprocal changes in tumor antigenicity and antigen-specific T cell function during tumor progression.

Authors:  Gang Zhou; Zhengbin Lu; John D McCadden; Hyam I Levitsky; Aimee L Marson
Journal:  J Exp Med       Date:  2004-12-13       Impact factor: 14.307

Review 3.  Defining Immunogenic and Radioimmunogenic Tumors.

Authors:  Terry R Medler; Tiffany C Blair; Marka R Crittenden; Michael J Gough
Journal:  Front Oncol       Date:  2021-03-19       Impact factor: 6.244

Review 4.  Development and therapeutic manipulation of the head and neck cancer tumor environment to improve clinical outcomes.

Authors:  Thomas Duhen; Michael J Gough; Rom S Leidner; Sasha E Stanton
Journal:  Front Oral Health       Date:  2022-07-22

5.  Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells.

Authors:  Mary Jo Turk; José A Guevara-Patiño; Gabrielle A Rizzuto; Manuel E Engelhorn; Shimon Sakaguchi; Alan N Houghton
Journal:  J Exp Med       Date:  2004-09-20       Impact factor: 14.307

6.  Antitumor effect of PSK: role of regional lymph nodes and enhancement of concomitant and sinecomitant immunity in the mouse.

Authors:  T Ebina; H Kohya; K Ishikawa
Journal:  Jpn J Cancer Res       Date:  1989-02

7.  Antitumor effector mechanism at a distant site in the double grafted tumor system of PSK, a protein-bound polysaccharide preparation.

Authors:  T Ebina; H Kohya
Journal:  Jpn J Cancer Res       Date:  1988-08
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.